| __timestamp | BioMarin Pharmaceutical Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 621276000 | 580006000 |
| Thursday, January 1, 2015 | 737887000 | 676585000 |
| Friday, January 1, 2016 | 907234000 | 778966000 |
| Sunday, January 1, 2017 | 1071860000 | 671251000 |
| Monday, January 1, 2018 | 1175948000 | 463508000 |
| Tuesday, January 1, 2019 | 1344582000 | 445724000 |
| Wednesday, January 1, 2020 | 1336183000 | 399725000 |
| Friday, January 1, 2021 | 1375760000 | 296656000 |
| Saturday, January 1, 2022 | 1612370000 | 293122000 |
| Sunday, January 1, 2023 | 1842161000 | 268323000 |
| Monday, January 1, 2024 | 2273680000 | 304979000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical industry, understanding financial health is crucial. This analysis focuses on the gross profit trends of two prominent players: BioMarin Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd., from 2014 to 2023.
BioMarin has shown a remarkable upward trajectory, with its gross profit increasing by nearly 200% over the decade, peaking at approximately $1.84 billion in 2023. This growth reflects BioMarin's strategic advancements in biotechnology and rare disease treatments. In contrast, Taro Pharmaceutical experienced a decline, with its gross profit dropping by over 50% from 2016 to 2023, reaching around $268 million. This decline may be attributed to market competition and regulatory challenges.
The data for 2024 is incomplete, highlighting the dynamic nature of the industry. These insights underscore the importance of strategic innovation and market adaptation in sustaining financial growth.
Gross Profit Trends Compared: Johnson & Johnson vs BioMarin Pharmaceutical Inc.
Johnson & Johnson vs Taro Pharmaceutical Industries Ltd.: A Gross Profit Performance Breakdown
AstraZeneca PLC and BioMarin Pharmaceutical Inc.: A Detailed Gross Profit Analysis
Gross Profit Comparison: Sanofi and Taro Pharmaceutical Industries Ltd. Trends
Gross Profit Trends Compared: Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Gross Profit Analysis: Comparing GSK plc and BioMarin Pharmaceutical Inc.
Biogen Inc. vs BioMarin Pharmaceutical Inc.: A Gross Profit Performance Breakdown
Gross Profit Analysis: Comparing Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Gross Profit Analysis: Comparing BioMarin Pharmaceutical Inc. and Vericel Corporation
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: A Gross Profit Performance Breakdown
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd.
Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.: A Gross Profit Performance Breakdown